亚洲欧美日韩中文在线制服,中文在线最新版天堂,制服 丝袜 国产,亚洲伊人久久大香线蕉,亚洲精品乱码久久久久久蜜桃

訂購(gòu)信息
上海拜力生物科技公司
Tel:400-968-7988    021-33779008
ABT-199,BCL-2inhibitor
品牌：Xcessbio
貨號(hào)：M60075-2s
規(guī)格：2 mg solid
貨期：
應(yīng)用： 點(diǎn)擊這里給我發(fā)消息  咨詢客服

ABT-199,BCL-2inhibitor
商品詳情 參考文獻(xiàn) 相關(guān)資料
Product Information
Chemical Name: (4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide)
Molecular Weight: 868.44
Formula: C45H50ClN7O7S
Purity: ≥ 98%
CAS#: 1257044-40-8
Solubility: DMSO up to 50 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year


Biological Activity:

ABT-199 is a highly potent, selective, and orally bioavailable BCL-2 inhibitor. ABT-199 has picomolar affinity for BCL-2 (Ki < 0.010 nM) and > 1000 folds selectivity over BCL-XL (Ki = 48 nM) and BCL-W (Ki = 245 nM). Therefore, ABT-199 is a much improved lead compound over the original ABT-263 (navitoclax) to avoid thrombocytopenia caused by BCL-XL inhibition. ABT-199’s cell-killing effect is selective and mechanism dependent. It can potently kill BCL-2-overexpressing FL5.12 cells (EC50 ~ 4 nM) and RS4;11 BCL-2–dependent ALL cells (EC50 ~8 nM), but showed much weaker activity against BCL-XL-overexpressing FL5.12 cells (EC50 ~261 nM) and H146 ALL cells (EC50 ~4,260 nM). ABT-199 inhibits the growth of BCL-2–dependent human hematological tumors in vivo and spares human platelets as a single agent or in combination with rituximab and bendamustine. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicates that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2–dependent hematological cancers.


How to Use:

In vitro:? ABT-199 was used at 0.1-1 μM final concentration in vitro and in cellular assays.

In vivo: ABT-199 was orally dosed to mice at 12.5-100 mg/kg once per day in combination with rituximab and Bendamustine, and significantly reduced tumor volume.


Reference:

    1. 1. Fresquet V, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. (2014) Blood. 123(26):4111-9.?
    2. 2. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. (2013) Nat Med. 19(2):202-8.
    3. 3. Roberts, A.W. et al. Selective inhibition of BCL-2 is active against chronic lymphocytic leukemia (CLL): first clinical experience with the BH3-mimetic ABT-199. Abstract 546 (European Hematology Association 2012, Amsterdam, The Netherlands, June 14–17, 2012).


        ? ? ?

        ? ? ?


        Products are for research use only. Not for human use.

        熱銷產(chǎn)品
        熱銷產(chǎn)品排行榜
        • 關(guān)于我們
        • 購(gòu)物流程
        • 支付方式
        • 配送方式

        請(qǐng)打開QQ掃碼聯(lián)系
        Copyright@ 2003-2025  進(jìn)口試劑采購(gòu)網(wǎng)版權(quán)所有     

        BIOLEAF熱搜   BIOLEAF試劑盒   BIOLEAF ELISA   BIOLEAF試劑   BIOLEAF品牌   BIOLEAF抗體   BIOLEAF耗材   BIOLEAF小儀器

        sitemap   細(xì)胞庫(kù)查詢   危險(xiǎn)品圖標(biāo)

        本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研！

                 滬ICP備08023583號(hào)-6     
        產(chǎn)品咨詢
        QQ掃碼溝通
        在線客服
        服務(wù)電話
        400-968-7988
        掃碼關(guān)注
        微信公眾號(hào)二維碼

        滬公網(wǎng)安備 31011202007338號(hào)